Needham initiated coverage of ZimVie with a rating of Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $20.00 | Hold → Buy | Needham |
| 11/16/2023 | Hold | Needham | |
| 12/21/2022 | $9.00 | Underweight | Barclays |
| 6/17/2022 | $20.00 | Neutral | JP Morgan |
| 3/18/2022 | Neutral | Guggenheim |
SCHEDULE 13G - ZimVie Inc. (0001876588) (Subject)
SCHEDULE 13G/A - ZimVie Inc. (0001876588) (Subject)
10-Q - ZimVie Inc. (0001876588) (Filer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
4 - ZimVie Inc. (0001876588) (Issuer)
SC 13G - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
SC 13G/A - ZimVie Inc. (0001876588) (Subject)
PALM BEACH GARDENS, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the fourth quarter and full-year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental mark
Third Party Net Sales from Continuing Operations of $103.2 millionNet Loss from Continuing Operations of $(3.0) million; Net Loss margin of (3.0%) Adjusted EBITDA[1] from Continuing Operations of $13.1 million; Adjusted EBITDA[1] margin of 12.7%GAAP diluted EPS from Continuing Operations of $(0.11) and adjusted diluted EPS of $0.12 PALM BEACH GARDENS, Fla., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call today, October 30, 2024, at 4:30 p.m. Eastern Time. "In the third quarter we saw an improvement
PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manu
Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00
Needham initiated coverage of ZimVie with a rating of Hold
Barclays initiated coverage of ZimVie with a rating of Underweight and set a new price target of $9.00
PALM BEACH GARDENS, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the fourth quarter and full-year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental mark
PALM BEACH GARDENS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the publication of a detailed scientific study demonstrating the surface texture of ZimVie's premium implants may help to lower the risk of peri-implant infections when compared to other commercially available implants. The study, titled "The Role of Implant Coronal Surface Properties on Early Adhesion of Streptococcus Oralis—An In Vitro Comparative Study," has been published in the Journal of Biomedical Materials Research, a leading journal in the field of biological and medical sciences. The study evaluated the innovative dual
Third Party Net Sales from Continuing Operations of $103.2 millionNet Loss from Continuing Operations of $(3.0) million; Net Loss margin of (3.0%) Adjusted EBITDA[1] from Continuing Operations of $13.1 million; Adjusted EBITDA[1] margin of 12.7%GAAP diluted EPS from Continuing Operations of $(0.11) and adjusted diluted EPS of $0.12 PALM BEACH GARDENS, Fla., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call today, October 30, 2024, at 4:30 p.m. Eastern Time. "In the third quarter we saw an improvement